Summary
Intuitive Surgical, Inc. (ISRG) reported its financial results for the second quarter and first half of 2013. Total revenue for the second quarter increased by 8% year-over-year to $578.5 million, and for the first half of the year, it grew by 15.2% to $1,189.9 million. This growth was primarily driven by an 18% increase in da Vinci surgical procedures globally, fueled by strong performance in U.S. general surgery and gynecology, as well as international urology procedures. Recurring revenue, consisting of instruments, accessories, and service, continued its robust growth, increasing by 18% in the quarter and 21% for the first half, representing a growing portion of total revenue. Despite top-line growth, operating income saw a slight decrease in the second quarter due to increased operating expenses, including higher SG&A costs related to organizational growth and legal expenses. The company also faced challenges such as moderating growth in U.S. benign gynecologic procedures, a decline in U.S. prostatectomy procedures, and the impact of new regulations like the U.S. medical device excise tax, which affected gross margins. The company ended the period with a strong cash position of $3.0 billion in cash, cash equivalents, and investments.
Financial Highlights
46 data points| Revenue | $578.50M |
| Cost of Revenue | $173.30M |
| Gross Profit | $405.20M |
| R&D Expenses | $41.20M |
| SG&A Expenses | $145.50M |
| Operating Expenses | $186.70M |
| Operating Income | $218.50M |
| Net Income | $159.10M |
| EPS (Basic) | $0.44 |
| EPS (Diluted) | $0.43 |
| Shares Outstanding (Basic) | 359.10M |
| Shares Outstanding (Diluted) | 367.20M |
Key Highlights
- 1Total revenue for Q2 2013 increased by 8% to $578.5 million, driven by an 18% rise in da Vinci procedures.
- 2Recurring revenue (instruments, accessories, and service) grew 18% in Q2 2013, reaching $362.6 million and comprising 63% of total revenue.
- 3Systems revenue saw a 6% decrease in Q2 2013 to $215.9 million, with 143 units sold compared to 150 in the prior year's quarter, particularly due to lower U.S. sales.
- 4Gross margin for products declined slightly due to the new U.S. medical device excise tax and lower margins on new product introductions.
- 5Operating income decreased by 3% to $218.5 million in Q2 2013, impacted by increased selling, general, and administrative expenses.
- 6The company's cash, cash equivalents, and investments stood at $3.0 billion as of June 30, 2013.
- 7Intuitive Surgical is facing increased litigation and negative media attention regarding the safety and efficacy of its da Vinci Surgical System, which could impact future growth.